

REMARKS

Claims 5 and 9 have been amended to incorporate SEQ ID Nos.

A Substitute Sequence listing has been provided along with a Computer Readable Form of the Sequence Listing. The undersigned hereby states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR 1.821, including 1.821(c) and 1.821(e) are identical. No new matter has been added by these amendments.

Favorable consideration of this application is respectfully requested.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6938

Myra H. McCormack
Myra H. McCormack, Ph.D.
Attorney for Applicants
Reg. No. 36,602

Date: February 14, 2000

FEB 28 2000
TECH CENTER 1600/2900